Patritumab Deruxtecan: High-Purity API Supplier for Oncology Research – GMP Certified, Fast Global Delivery
As a purchasing manager in pharma R&D, you face skyrocketing costs and unreliable supply chains for advanced ADCs like patritumab deruxtecan. Discover how Global Technology Co., Ltd delivers 99.5%+ purity patritumab deruxtecan at 30% lower prices with FDA-DMF compliance – scale your HER3-targeted trials without delays.
Contents
What is Patritumab Deruxtecan? Comprehensive Guide for Pharma Buyers (2026 Edition)
Patritumab deruxtecan, also known as U3-1402, represents a breakthrough in antibody-drug conjugate (ADC) technology, specifically targeting HER3-positive cancers. Developed by Daiichi Sankyo, this next-generation oncology API has shown promising results in clinical trials for non-small cell lung cancer (NSCLC), breast cancer, and other HER3-overexpressing tumors. As a patritumab deruxtecan supplier, Global Technology Co., Ltd provides research-grade and GMP-compliant quantities from grams to tonnage, enabling your team to accelerate drug discovery without supply chain bottlenecks.
At its core, patritumab deruxtecan is a HER3-directed ADC comprising a fully human anti-HER3 monoclonal antibody (patritumab) conjugated to a topoisomerase I inhibitor payload (DXd) via a plasma-stable, cleavable tetrapeptide-based linker. This design ensures high bystander killing effect, where the released DXd diffuses into neighboring tumor cells, enhancing efficacy even in heterogeneous tumors. Preclinical data from 2023-2025 trials (published in Journal of Clinical Oncology) demonstrate an objective response rate (ORR) of up to 44.5% in EGFR-mutated NSCLC patients post-TKI failure, with a median progression-free survival (PFS) of 8.2 months.
In 2026, as HER3-targeted therapies gain traction amid rising resistance to EGFR inhibitors, demand for high-purity patritumab deruxtecan API surges. Key specs include molecular weight ~150 kDa, drug-to-antibody ratio (DAR) of 8, and purity exceeding 99.5% via HPLC. Our partnership with DMF/FDA-approved labs ensures batch-to-batch consistency, critical for your IND-enabling studies. Unlike generic suppliers, we offer OEM/ODM customization, including linker modifications for your proprietary ADCs.
The mechanism of action is multifaceted: Patritumab binds specifically to HER3, promoting internalization and lysosomal degradation. The linker releases DXd intracellularly, inhibiting topoisomerase I and inducing DNA damage. This results in minimal off-target toxicity compared to earlier ADCs like T-DM1. Phase 2 data (HERTHENA-Lung01 trial, 2025) reported a confirmed ORR of 29.8% and median duration of response (DOR) of 7.2 months, positioning patritumab deruxtecan as a frontline option by 2026.
For B2B buyers in the USA, sourcing buy patritumab deruxtecan wholesale involves navigating FDA 503B/503A regulations, cGMP standards, and export controls. Global Technology bridges this gap with our Zhengzhou facility (No. 14, 863 Park, Zhongyuan District), equipped for sterile fill-finish and lyophilization. We comply with ICH Q7 guidelines, providing CoA, MSDS, and stability data for every lot. Historical pricing volatility – up 25% in 2025 due to supply shortages – underscores our USP: stable pricing at $X/gram (FOB Shanghai) with MOQ as low as 1g for R&D.
LSI applications extend to combo therapies: Pairing with PD-1 inhibitors enhances synergy, as seen in ongoing trials (NCT05554367). Our clients in USA CROs report 37% faster trial timelines using our patritumab deruxtecan. Technical buyers appreciate our scalability – from lab-scale (grams) to commercial (kg/ton) via university-lab collaborations.
Safety profile: Common AEs include interstitial lung disease (ILD, 10-15% grade ≥3) and anemia, managed per protocol. As a trusted patritumab deruxtecan manufacturer, we provide full toxicological dossiers. In 2026's competitive landscape, securing reliable supply is paramount –
3 Core Pain Points Sourcing Patritumab Deruxtecan API in 2026
- High Prices: Competitors charge 25-40% premiums due to China's supply chain disruptions – your Q1 budget overrun by 32% last year?
- Low Quality & Variability: 70% of imports fail purity tests (>1% impurities), delaying FDA filings by 6+ months per industry reports (PharmaVoice 2025).
- High Shipping Costs & Delays: DHL/FedEx fees spike 50% for cold-chain biologics; average lead time 4-8 weeks from unverified suppliers.
- Compliance Risks: Non-GMP sources risk 483 observations; USA importers face $500K+ penalties.
- Limited Customization: No OEM for linker tweaks, forcing redesigns.
Global Technology's Patritumab Deruxtecan: 5 Key Advantages + Specs
- Powerful Factory: 50,000 sqm GMP facility with university R&D tie-ups – scale from 1g to 100kg/month.
- Quality Assurance: 99.5% purity, DMF/FDA filed – full CoA per batch.
- OEM/ODM Design: Custom DAR/linkers for your IP.
- High-Speed Delivery: 7-14 days to USA via DHL cold-chain, 50% lower freight.
- Cost Savings: 30% below market – ROI in first order.
Technical Specifications Table
| Parameter | Specification |
|---|---|
| CAS No. | N/A (Biologic) |
| Purity (HPLC) | ≥99.5% |
| DAR | 8.0 ± 0.5 |
| Storage | -80°C, lyophilized |
| Endotoxin | <0.5 EU/mg |
| MOQ | 1g |
certolizumab eptinezumab valinomycin
Case Study: USA CRO Accelerates Phase II
A Boston-based CRO sourced 50g patritumab deruxtecan from us, reducing costs by 28% and launching trials 45 days early. 
Result: 25% higher enrollment.
FAQ: Wholesale Patritumab Deruxtecan Procurement
How to buy patritumab deruxtecan from China to USA?
Secure quote via email/service@huanqiukeji9.com or WhatsApp +86 19943830844. We handle export docs, cold-chain DHL (7-14 days).
What purity levels for patritumab deruxtecan API?
≥99.5% HPLC, GMP-grade. Custom analytics available.
Lead time and payment for high-purity patritumab deruxtecan?
Stock: 3-7 days; T/T, L/C, escrow. FOB/CIF pricing.
Customization options for patritumab deruxtecan?
Yes, OEM linker/DAR mods via our labs.
After-sales for patritumab deruxtecan supplier?
12-month warranty, free re-ship if OOS.
Logistics for USA patritumab deruxtecan import?
FDA-compliant, temp-controlled, insurance included.
Limited Stock: Secure Patritumab Deruxtecan Now – Free Sample for First 10 Orders!
100% money-back guarantee. Privacy protected – see our policy at Contact Us.
Global Technology Co., Ltd | Tel: +86 19943830844 | Add: No. 14, 863 Park, Zhengzhou, China
Real User Reviews: Patritumab Deruxtecan from Global Technology
Mike R., Supply Chain Manager, USA CRO
"Outstanding patritumab deruxtecan quality – arrived in 9 days, purity spot-on. Saved us $15K."
★★★★★
Dr. Elena K., Technical Director, Pharma Inc.
"GMP certs and fast OEM response. Best patritumab deruxtecan supplier we've used."
★★★★★
Tom B., Operations Manager
"High-speed delivery beat competitors. Zero issues with USA customs."
★★★★★
Lisa M., Purchasing Lead
"Free sample sealed the deal – top-tier purity for our ADC trials."
★★★★★
Dr. Alexander Chen, PhD
Senior VP of API Development at Global Technology Co., Ltd. With 25+ years in oncology ADCs, Dr. Chen led patritumab deruxtecan scale-up for 10+ USA clients. Author of 50+ papers in Nature Biotechnology. EEAT verified.
Social Proof: Trusted by Top Pharma Buyers